Surrogate end points and FDA approval: A tale of 2 lipid-altering drugs

JAMA

Volumn 299, Issue 12, 2008, Pages 1474-1476

  Psaty, Bruce M ^a,c   Lumley, Thomas ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TORCETRAPIB; AZETIDINE DERIVATIVE; BIOLOGICAL MARKER; QUINOLINE DERIVATIVE;

CARDIOVASCULAR DISEASE; DRUG APPROVAL; DRUG MARKETING; DRUG WITHDRAWAL; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; ARTICLE; CLINICAL TRIAL; RISK; UNITED STATES;

ANTILIPEMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; QUINOLINES; RISK; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 41149128233     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.12.1474     Document Type: Note

References (21)

1. Division of Metabolic and Endocrine Drug Products; US Food and Drug Administration. Guidelines for the clinical evaluation of lipid-altering agents in adults and children: Center for Drug Evaluation and Research, September 1990. http://www.fda.gov/cder/guidance/lipid.pdf. Accessed March 1, 2008.
2. Knopp RH, Gitter H, Truitt T, et al; Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24(8):729-741.
3. Dujovne CA, Ettiger MP, McNeer JF, et al; Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, exetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1092-1097.
4. Gagné C, Bays HE, Weiss SR, et al; Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1084-1091.
5. Davidson MH, McGarry T, Bettis R, et al; Ezetimibe Study Group. Ezetimibe coadministerted with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40(12):2125-2134.
6. Berenson A. Study reveals doubt on drug for cholesterol. New York Times. January 15, 2008:A1. http://www.nytimes.com. Accessed January 15, 2008.
7. Merck/Schering-Plough Pharmaceuticals. Product news: Merck/Shering-Plough Pharmaceuticals provides results of the ENHANCE trial, January 14, 2008. http://www.merck.com/newsroom/press_releases/product/2008_0114.html. Accessed January 15, 2008.
8. Hellings WE, Moll FL, De Vries J, et al. Atherosclerotic plaque composition and occurrence of restenosis after carotid endarterectomy. JAMA. 2008;299(5):547-554.
9. Psaty BM, Anderson M, Kronmal RA, et al. The association between lipid levels and the risks of incident myocardial infarction, stroke and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc. 2004;52(10):1639-1647.
10. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350(15):1505-1515.
11. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48(9):1774-1781.
12. McKenney JM, Davidson HM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inihibitor, in individuals with below-average high-density lipoprotein cholesterol levels on background of atorvastatin. J Am Coll Cardiol. 2006;48(9):1782-1790.
13. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304-1316.
14. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370(9582):153-160.
15. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-2122.
16. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005;294(14):1773-1781.
17. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2472.
18. Joffe HV, Parks MH, Meyer RJ, Jenkins JK, Temple R. Rosiglitazone and the FDA. N Engl J Med. 2007;357(17):1775-1776.
19. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease. JAMA. 1999;282(8):786-790.
20. Greenland P, Lloyd-Jones D. Critical lessons from the ENHANCE trial. JAMA. 2008;299(8):953-955. doi:10.1001/jama.298.1.jed70037.
21. US Food and Drug Administration. Amendments Act of 2007: HR 3580, enacted by the House and Senate, Pub L No. 110-85. http://frwebgate.access.gpo.gov/cgi- bin/getdoc.cgi?dbname=110_cong_bills&docid=f:h3580enr.txt.pdf. Accessed October 11, 2007.